Long-Term Outcomes With CNP Analogue Therapy in Achondroplasia

In “Long-Term Outcomes With CNP Analogue Therapy in Achondroplasia,” our panel explores clinical data evaluating vosoritide in infants and children younger than 5 years of age. The panel reviews studies that enrolled children across several early-age cohorts, including infants younger than 6 months, children between 6 months and 2 years, and children between 2 and 5 years. Once an appropriate dose had been established, investigators assessed annualized growth velocity and incorporated imaging of the brain and foramen magnum to better understand the effects of treatment during early skeletal development.

The experts discuss improvements in annualized growth velocity relative to expected achondroplasia growth trajectories, while noting that the magnitude of the response in younger children appeared smaller than that observed in older pediatric populations. They also highlight emerging observations involving skull-base structures in very young children, although the available data remain insufficient to draw definitive conclusions regarding these outcomes.

Safety is an important component of the discussion. The panel notes that faster skeletal growth did not appear to worsen skull-base narrowing or compression, addressing an early theoretical concern about accelerating bone growth in children already at risk for stenosis. The panel also reviews placebo-controlled data in children younger than 60 months, including changes in height Z-score and a favorable overall safety profile. Together, these studies provide growing experience with initiating treatment earlier in childhood while underscoring the need for continued long-term follow-up.

Our next episode, “Evaluating Long-Acting CNP Therapy in Achondroplasia,” turns to a once-weekly CNP prodrug. The panel will discuss its mechanism, pivotal ApproaCH trial findings, safety, and longer-term outcomes related to growth and skeletal alignment.